Answers are grounded in this paper and cite their sources.
Immunotherapy has transformed the therapeutic landscape of onco-hematology, evolving from historical allogeneic hematopoietic stem cell transplantation (HSCT) to modern chimeric antigen receptor (CAR) T/NK cell therapies, bispecific antibodies, and immune checkpoint inhibitors. Central to this immunological cross-talk is the Human Leukocyte Antigen (HLA) system, which governs self/non-self-discrimination, alloreactivity, and tumor immune evasion across both classical allografts and novel adoptive cellular platforms. Facing hematological malignancies, ranging from acute leukemias and multiple myeloma to chronic leukemias and lymphomas, clinicians must overcome tumor immune escape while managing treatment-related toxicities and Graft-versus-Host Disease (GvHD). Advances in high-throughput molecular biology techniques, notably Next-Generation Sequencing (NGS) and long-read sequencing, have become indispensable for high-resolution HLA matching, minimal residual disease (MRD) monitoring, and chimerism analysis. Furthermore, gene-editing strategies (e.g., CRISPR/Cas9) targeting TRAC, B2M, and CIITA, alongside HLA-E engineering and induced pluripotent stem cell (iPSC) technology, are driving the development of universal “off-the-shelf” effector platforms that bypass classic HLA barriers. In this review, we provide a conceptual synthesis of immunotherapeutic paradigms in onco-hematology, highlighting the pivotal role of HLA biology and molecular diagnostics in shaping next-generation personalized cellular therapies.
No takes yet. Share an insight, caveat, or question.
Picard et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: